Intra-Cellular Therapies Price to Sales Ratio 2013-2022 | ITCI

Historical PS ratio values for Intra-Cellular Therapies (ITCI) over the last 10 years. The current P/S ratio for Intra-Cellular Therapies as of July 01, 2022 is . For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Intra-Cellular Therapies P/S Ratio Historical Data
Date Stock Price TTM Sales per Share Price to Sales Ratio
2022-07-01 55.17 45.46
2022-03-31 61.19 $1.21 50.42
2021-12-31 52.34 $1.03 50.72
2021-09-30 37.28 $0.89 41.75
2021-06-30 40.82 $0.73 56.23
2021-03-31 33.93 $0.51 66.81
2020-12-31 31.80 $0.33 96.86
2020-09-30 25.66 $0.15 169.57
2020-06-30 25.67 $0.05 566.12
2020-03-31 15.37 $0.02 923.56
2019-12-31 34.31 0 0.00
2019-09-30 7.47 0 0.00
2019-06-30 12.98 0 0.00
2019-03-31 12.18 0 0.00
2018-12-31 11.39 0 0.00
2018-09-30 21.70 $0.00 0.00
2018-06-30 17.67 $0.00 0.00
2018-03-31 21.05 $0.00 0.00
2017-12-31 14.48 $0.01 0.00
2017-09-30 15.78 $0.01 0.00
2017-06-30 12.42 $0.01 0.00
2017-03-31 16.25 $0.01 0.00
2016-12-31 15.09 $0.01 0.00
2016-09-30 15.24 $0.01 0.00
2016-06-30 38.82 $0.01 0.00
2016-03-31 27.80 $0.00 0.00
2015-12-31 53.79 $0.00 0.00
2015-09-30 40.04 $0.00 0.00
2015-06-30 31.95 $0.01 0.00
2015-03-31 23.88 $0.01 1690.04
2014-12-31 17.65 $0.02 866.88
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $5.204B $0.084B
Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00